GlassScriptPhysician profile
Indira Madapati
NPI 1972646487
$4,231.40
in general payments reported to CMS, 2019-2025
28 companies · $450 in 2025
The $450 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $725 · 2021: $822 · 2022: $345 · 2023: $449 · 2024: $384 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,282.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,333.97 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $404.47 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $312.83 | 2021-2023 | |
| Amgen INC. | $244.55 | 2019-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $244.24 | 2019-2021 | |
| Glaxosmithkline, LLC. | $213.42 | 2019-2025 | Trelegy Ellipta |
| Medtronic Minimed, INC. | $200.02 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $186.14 | 2019-2023 | Belsomra, Steglatro |
| Novo Nordisk INC | $167.03 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Allergan, INC. | $156.99 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.51 | 2020-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $102.16 | 2019 | |
| Abbott Laboratories | $96.86 | 2019-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $93.43 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $72.65 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.75 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $33.32 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $30.75 | 2025 | Zoryve |
| Indivior INC. | $25.49 | 2019 | |
| Phadia US INC. | $21.84 | 2024 | Immunocap |
| Biogen, INC. | $21.29 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $17.12 | 2023 | Crysvita |
| Boston Scientific Corporation | $16.25 | 2023 | |
| Xeris Pharmaceuticals, INC. | $14.65 | 2023 | Gvoke Hypopen |
| Dermira, INC. | $13.78 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.77 | 2020 | |
| Genentech USA, INC. | $11.92 | 2020 | |
| Pfizer INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indira Madapati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.